Quantcast
Last updated on April 20, 2014 at 8:28 EDT

U.S. Patent and Trademark Office Issues Mylan’s Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution

January 12, 2009

PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ — Mylan Inc. (Nasdaq: MYL)
today announced that its subsidiary Dey L.P. has been issued several
additional U.S. patents protecting the company’s Perforomist(R) Inhalation
Solution, a chronic obstructive pulmonary disease (COPD) treatment.

U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to
treatment through the administration of a ready-to-use, storage stable
composition of formoterol. This patent covers Dey’s Perforomist(R) Solution,
and its term extends until June 22, 2021. The patent will be listed in the
“Orange Book,” giving Dey four Orange Book-listed patents covering Perforomist
Solution.

U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and
Jan. 6, 2009, respectively. These patents are directed to compositions of
“R-formoterol,” a specific form of the formoterol molecule, and their use.

In addition, Dey has received a “Notice of Allowance” on yet another
patent also directed to the use of R-formoterol. This patent is expected to
issue shortly. Upon its issuance, Dey will possess seven patents directed to
compositions of formoterol, R-formoterol and/or their uses.

Mylan’s Vice Chairman and CEO Robert J. Coury stated: “We are very pleased
with the recent issuance of these additional patents, which we believe only
further bolster Dey’s already strong intellectual property portfolio, and we
will continue to aggressively protect and assert Dey’s IP rights. Dey is
currently pursuing a patent infringement lawsuit against Sepracor relating to
its Brovana(R) product.”

Dey also has additional pending U.S. patent applications directed to
formoterol-containing compositions and their use in the treatment of
respiratory conditions.

Mylan Inc., which provides products to customers in more than 140
countries and territories, ranks among the leading diversified generic and
specialty pharmaceutical companies in the world. The company maintains one of
the industry’s broadest – and highest quality – product portfolios, supported
by a robust product pipeline; owns a controlling interest in the world’s third
largest active pharmaceutical ingredient manufacturer; and operates a
specialty business focused on respiratory and allergy therapies. For more
information, please visit www.mylan.com.

Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty
pharmaceutical company focused on the development, manufacturing and marketing
of prescription drug products for the treatment of respiratory diseases,
respiratory-related allergies and emergency care medicine. As the U.S. leader
in sales of nebulized respiratory medication, Dey L.P. puts patients first
through its development of innovative and affordable therapies. The Web sites
for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com,
www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.

SOURCE Mylan Inc.


Source: newswire